Taiwan’s MegaPro Biomedical Co (巨生生醫) and China Chemical & Pharmaceutical Co (CCPC, 中國化學製藥) yesterday announced that they have set up a joint venture with China’s Wellbridge Biotech Ltd (蘇州瑋琪) focusing on the development of drugs in inhalation dosage forms.
MegaPro said it would invest about US$600,000 for a 30 percent stake in the joint venture — Trium Therapeutics Co — while CCPC and Wellbridge would hold 40 percent and 30 percent respectively.
Trium’s chairman and general manager are to be appointed by CCPC and MegaPro respectively, it said.
Photo: Grace Hung, Taipei Times
Trium’s main research goal is to meet pharmaceutical companies’ demand for non-invasive routes of drug administration, such as via the nasal cavity, to improve patients’ comfort and drugs’ bioavailability, MegaPro said.
MegaPro would utilize its expertise in improving drug delivery technology and develop new dosage forms on its nano-platform technology, it said.
MegaPro would also be responsible for conducting animal tests and human trials, it added.
CCPC, which operates Good Manufacturing Practice-certified pharmaceutical plants, as well as sales channels at home and abroad, would be responsible for mass production and marketing, while Wellbridge, which specializes in medical nebulizers, would provide technical information for the development of inhalation dosage forms and supply nebulizer equipment, the companies said.
“Oral dosage forms have been well-developed and widely used by generic drug manufacturing pharmaceutical companies. How to expand special treatment pathways has become the next phase of development in the pharmaceutical industry,” CCPC general manager Wu Zhi-yong (吳志庸) said in a statement.
Reports by Data Bridge Market Research Private Ltd, a professional research company, show that the global market for inhalers is expected to reach US$42.1 billion in 2027, with a compound annual growth rate of 5.87 percent from this year to 2027, MegaPro said.
As patients inhale the drug, its main components can be quickly absorbed by the lungs and dense blood capillaries, it said.
Trium has completed the screening of drug candidates and the preliminary animal tests, and would carry out stability tests and more animal tests, the companies said.
Spun off in 2014 from the Industrial Technology Research Institute, MegaPro focuses on developing niche nano-medicines and holds two proprietary nanotechnology platforms, with three product pipelines treating iron deficiency anemia and hepatocellular carcinoma.
MegaPro reported zero revenue for the first half of this year, while CCPC’s revenue was flat from a year earlier at NT$4.03 billion (US$135.2 million), companies’ data showed.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday obtained the government’s approval to inject an additional US$10.26 billion to finance the construction of its second fab in Kumamoto, Japan, and a second fab in Arizona, using advanced process technologies. The Department of Investment Review approved TSMC’s investment applications on the basis that Taiwan remains a major technology and manufacturing hub for the chipmaker, which makes its most advanced chips at home, the company operates its research-and-development center here and the majority of its capacity remains in Taiwan. The latest capital injections — US$5.26 billion for its Japanese venture Japan Advanced Semiconductor Manufacturing
Packed into a small room, a drone, bipedal robot, supermarket checkout and other devices showcase a vision of China’s software future — one where an operating system developed by national champion Huawei (華為) has replaced Windows and Android. The collection is at the Harmony Ecosystem Innovation Center in the southern city of Shenzhen, a local government-owned entity that encourages authorities, companies and hardware makers to develop software using OpenHarmony (鴻蒙), an open-source version of the operating system Huawei launched five years ago after US sanctions cut off support for Google’s Android. While Huawei’s recent strong-selling smartphone launches have been closely watched for
The waves of the Aegean Sea lap gently at the tables and chairs of two beach restaurants on Greece’s Halkidiki peninsula. It is an idyllic scene, but one that is totally illegal. Like many others in Greece, the two establishments on Pefkochori Beach do not have a license to set up shop so close to the water. After a wave of protests last summer by locals about bars and restaurants illegally covering beaches with sunbeds and tables, the Greek state is taking action. It is cracking down on rogue tourist practices with surveillance drones, satellite imagery and a special app
South Korea’s SK Hynix Inc, the world’s No. 2 memorychip maker, is to invest 103 trillion won (US$74.6 billion) through 2028 to strengthen its chips business, focusing on artificial intelligence (AI), its parent SK Group said yesterday. SK Group also said it plans to secure 80 trillion won by 2026 to invest in AI and semiconductors as well as fund shareholder returns, while streamlining its more than 175 subsidiaries. The sprawling conglomerate outlined the plans following a two-day strategy meeting, aiming to revive the group after SK Hynix, its main money maker, and the group’s electric vehicle battery arm suffered heavy losses. SK